By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cepheid reported after the close of the market Thursday that its third-quarter revenues jumped 25 percent and its non-GAAP net income more than doubled on strong clinical sales.

The Sunnyvale, Calif.-based molecular diagnostics firm brought in total revenues of $70.2 million for the three months ended Sept. 30, compared to $56.1 million for the third quarter of 2010. It beat analysts' consensus estimate for revenues of $68.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.